2026 年 1 月 9 日,医麦客新闻 eMedClub News近期,GSK 宣布其用于治疗慢性乙型肝炎(CHB)的反义寡核苷酸(ASO)疗法 Bepirovirsen 在两项关键性 III 期临床试验(B-Well 1 和 B-Well 2)中取得了积极结果。这两项试验涵盖了在 29 个国家的 1800 余名患者,结果显示 Bepirovirsen 展现出了具有统计学意义和临床意义的功能性...
Source Link2026 年 1 月 9 日,医麦客新闻 eMedClub News近期,GSK 宣布其用于治疗慢性乙型肝炎(CHB)的反义寡核苷酸(ASO)疗法 Bepirovirsen 在两项关键性 III 期临床试验(B-Well 1 和 B-Well 2)中取得了积极结果。这两项试验涵盖了在 29 个国家的 1800 余名患者,结果显示 Bepirovirsen 展现出了具有统计学意义和临床意义的功能性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.